Home/Investors/Surveyor Capital

Surveyor Capital

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$3.6B

Focus Areas

5

Top Stage

Phase 1/2

Investment Focus

Neuromuscular Diseases Genetic Disorders Neuroscience Immunology Inflammation

Portfolio Companies

Company	Stage	Valuation	Focus
Dyne Therapeutics	Phase 1/2	$3.1B	Neuromuscular Diseases, Genetic Disorders
Contineum Therapeutics	Phase 2	$509.6M	Neuroscience, Immunology

Frequent Co-Investors

Public market investors1 shared Atlas Venture1 shared Vertex Ventures HC1 shared Dexcel Pharma1 shared Pivotal Bioventure Partners1 shared Vida Ventures1 shared MPM Capital1 shared New Leaf Venture Partners1 shared